Early Use of Ibuprofen in Moderate Cases of COVID-19 Might be a Promising Agent to Attenuate the Severity of Disease: A Randomized Controlled Trial

Sobhy et al., The Open Anesthesia Journal, doi:10.2174/25896458-v17-e230403-2022-26, PACTR202202880140319

Sobhy et al., Early Use of Ibuprofen in Moderate Cases of COVID-19 Might be a Promising Agent to Attenuate the Severity of.., The Open Anesthesia Journal, doi:10.2174/25896458-v17-e230403-2022-26, PACTR202202880140319

Apr 2023 Source PDF

Twitter
Facebook

All Studies Meta

RCT 180 moderate hospitalized COVID-19 patients in Egypt, showing lower ICU admission and shorter hospitalization with ibuprofen compared with acetaminophen.

Important missing comments or errors? Let us know.

This study includes acetaminophen and ibuprofen.

risk of ICU admission, 52.4% lower, RR 0.48, p = 0.047, treatment 10 of 90 (11.1%), control 21 of 90 (23.3%), NNT 8.2.

risk of oxygen therapy, 52.4% lower, RR 0.48, p = 0.047, treatment 10 of 90 (11.1%), control 21 of 90 (23.3%), NNT 8.2.

hospitalization time, 26.3% lower, relative time 0.74, p = 0.01, treatment 90, control 90.

risk of no recovery, 25.0% lower, RR 0.75, p = 1.00, treatment 3 of 90 (3.3%), control 4 of 90 (4.4%), NNT 90, day 4, dyspnea.

risk of no recovery, 42.9% lower, RR 0.57, p = 0.25, treatment 8 of 90 (8.9%), control 14 of 90 (15.6%), NNT 15, day 4, fever.

risk of no recovery, 48.0% lower, RR 0.52, p = 0.04, treatment 13 of 90 (14.4%), control 25 of 90 (27.8%), NNT 7.5, day 4, lymphopenia.

risk of no recovery, 41.2% lower, RR 0.59, p = 0.03, treatment 20 of 90 (22.2%), control 34 of 90 (37.8%), NNT 6.4, day 4, cough.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Sobhy et al., 19 Apr 2023, Double Blind Randomized Controlled Trial, Egypt, peer-reviewed, 6 authors, study period January 2022 - May 2022, this trial compares with another treatment - results may be better when compared to placebo, trial PACTR202202880140319.

Contact: dr.amrsobhy2013@gmail.com.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Ibuprofen All

Abstract: 1874-3218/23 Send Orders for Reprints to reprints@benthamscience.net 1 The Open Anesthesia Journal Content list available at: https://openanesthesiajournal.com CLINICAL TRIAL STUDY Early Use of Ibuprofen in Moderate Cases of COVID-19 Might be a Promising Agent to Attenuate the Severity of Disease: A Randomized Controlled Trial Amr Sobhy1,*, Lobna A. Saleh2, Marwa E.l AbdelAtty3, Ahmed M. AbdElmaksoud1, Sameh A. Refaat1 and Mohammed Kamal1 1 Department of Anesthesia, Intensive Care and Pain Management, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt Department of Clinical Pharmacology, Faculty of Medicine, Ain-Shams University, Cairo, Egypt 3 Department of Chest, Giza Chest Hospital, Cairo, Egypt 2 Abstract:

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit